UNSPSC 51381908: Oxolamine hydrochloride

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H19N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SHI14LG2ZY, chemically known as 1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl-, monohydrochloride, but more generally known as oxolamine hydrochloride, which bears US NIH Compound Identifier 14637. European Medicines Agency schedules oxolamine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09547MIG.

Most nations, for tariff purposes, schedule oxolamine hydrochloride under HS 29349990. SMILES: CCN(CC)CCC1NC(NO1)C2CCCCC2.CL.

UNSPSC 51381908 Oxolamine hydrochloride is a Commodity code that nominally designates a single active pharmaceutical ingredient, but recent state and local procurement activity tagged under this code shows little direct solicitation for oxolamine itself. Instead, the opportunities reveal a broader pattern of health and human services agencies buying finished pharmaceutical products—naloxone, generic multi-source drugs, and OTC medications—through centralized purchasing mechanisms. The issuing bodies span state health departments (Texas HHS Commission), county health authorities (Seminole County, Florida), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). This suggests the code may be used loosely by procurement offices to capture pharmaceutical procurement activity more broadly rather than oxolamine in isolation.

Recent activity concentrates in Florida, Texas, and Minnesota, with the most concrete solicitation being Seminole County's IFB 60459723LAS (posted June 30, 2026, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Texas HHS Commission issued RFI HHS0017013 (posted April 3, 2026) to explore direct-to-manufacturer prescription programs, an exploratory mechanism that precedes formal RFP issuance. The Minnesota Department of Administration's MMCAP office released RFP S1070000015802 (posted January 20, 2026, response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities, requiring vendor contracts with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and compliance with cGMP, DSCSA, and FDA requirements. All three opportunities emphasize supply chain security, regulatory compliance (E-Verify, federal environmental standards where FEMA-funded), comprehensive insurance coverage, and wholesale distribution partnerships rather than direct retail or clinical delivery.